Molecular Therapies of Cancer

INTRODUCTION

SECTION I: GENERAL PRINCIPLES

SECTION II: MOLECULAR TARGETING OF CANCER CELLS

1. DNA DAMAGING DRUGS
1.1. ALKYLATING AGENTS
1.2. ANTIBIOTICS
1.3. TOPOISOMERASE INHIBITORS
1.4. ANTI-METABOLITES

2. DRUGS THAT SUPPRESS PROLIFERATION
2.1. ANTI-MITOTIC AGENTS
2.2. DIFFERENTIATING AGENTS
2.3. INDUCERS OF APOPTOSIS

3. MOLECULAR INHIBITORS OF GROWTH SIGNALS
3.1. SMALL MOLECULE KINASE INHIBITORS
3.2. INHIBITORS OF ONCOGENE FUNCTIONS
3.3. ANTIBODIES

4. ANTI-METASTASIS THERAPY
4.1. INTEGRIN INHIBITORS
4.2. CD44 INHIBITORS
4.3. MMP INHIBITORS
4.4. CHEMOKINE RECEPTOR INHIBITORS
4.5. TGF- IHIBITORS
4.6. BONE TARGETING AGENTS
4.7. OTHERS

5. INDUCTION OF SENESCENCE
5.1. TELOMERASE INHIBITORS

6. COMBINATION CHEMOTHERAPY
6.1. TREATMENT OF HEMATOLOGIC MALIGNANCIES
6.2. TREATMENT OF SOLID TUMORS

SECTION III: EMERGING AND ALTERNATIVE TREATMENT MODALITIES

7. GENE THERAPY
7.1. GENE SILENCING
7.2. SUICIDE GENES
7.3. ONCOLYTIC VIRUSES
7.4. GENE DELIVERY
7.5. OTHER STRATEGIES

8. DRUGS WITH DIVERSE MODES OF ACTION

SECTION IV: MOLECULAR TARGETING OF TUMOR-HOST INTERACTIONS

9. HORMONE THERAPY
9.1. ANTI-ESTROGENS
9.2. ANTI-ANDROGENS
9.3. CORTICOSTEROIDS

10. IMMUNOTHERAPY
10.1. IMMUNOTOXINS
10.2. ENGINEERED ANTIBODIES
10.3. ANTIGEN BASED IMMUNOTHERAPIES
10.4. CYTOKINE BASED IMMUNOTHERAPIES
10.5. IMMUNE RESPONSE MODIFIERS
10.6. AUTOLOGOUS THERAPIES
10.7. OTHER REGIMENS

11. ANTI-ANGIOGENESIS
11.1. VEGF ANTAGONISTS
11.2. FGF-2 ANTAGONISTS
11.3. THALIDOMIDE RELATED DRUGS
11.4. INTEGRIN BLOCKERS
11.5. ENDOSTATIN AND ANGIOSTATIN
11.6. OTHERS

SECTION V: ANTI-CANCER DRUG PHARMACOKINETICS

12. DRUG DELIVERY AND DRUG TRANSPORT
12.1. TARGETING WITH DRUG CONJUGATES
12.2. RADIO-TARGETING
12.3. NANO-PARTICLES
12.4. SOLUBILIZERS
12.5. VARIOUS



13. DRUG METABOLISM
13.1. CYP450
13.2.

Georg Weber, MD, PhD, is Associate Professor at the James L. Winkle College of Pharmacy at the University of Cincinnati. Dr. Weber has made contributions to metastasis research by discovering the interaction between the molecules osteopontin and CD44 and by defining the physiologic role of metastasis genes as stress response genes. While he continues to address fundamental questions, he is researching new venues for diagnosis and therapy of cancer progression. Dr. Weber's professional affiliations include the American Association for the Advancement of Science, American Medical Association, American Association for Cancer Research, and Metastasis Research Society. Dr. Weber has published several books including Molecular Mechanisms of Cancer, which was published by Springer.